Donor Lymphocyte Infusions (DLI): Guidelines ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Author(s) :
De Vos, John [Auteur]
Baudoux, Etienne [Auteur]
Bay, Jacques-Olivier [Auteur]
Calmels, Boris [Auteur]
Cras, Audrey [Auteur]
El Cheikh, Jean [Auteur]
Guerout-Verite, Marie-Agnes [Auteur]
Lacassagne, Marie-Noelle [Auteur]
Lamure, Sylvain [Auteur]
Letellier, Catherine [Auteur]
Menard, Anne-Lise [Auteur]
Daguindau, Etienne [Auteur]
Poire, Xavier [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Guillaume, Thierry [Auteur]
Baudoux, Etienne [Auteur]
Bay, Jacques-Olivier [Auteur]
Calmels, Boris [Auteur]
Cras, Audrey [Auteur]
El Cheikh, Jean [Auteur]
Guerout-Verite, Marie-Agnes [Auteur]
Lacassagne, Marie-Noelle [Auteur]
Lamure, Sylvain [Auteur]
Letellier, Catherine [Auteur]
Menard, Anne-Lise [Auteur]
Daguindau, Etienne [Auteur]
Poire, Xavier [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Guillaume, Thierry [Auteur]
Journal title :
Bulletin du cancer
Abbreviated title :
Bull Cancer
Publication date :
2018-12-20
ISSN :
1769-6917
English keyword(s) :
Cellular immunotherapy
Donor lymphocyte infusion
Allogeneic stem cell transplantation
Donor lymphocyte infusion
Allogeneic stem cell transplantation
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and ...
Show more >Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and low-grade lymphomas while the anti-tumoral activity is less in forms of acute leukemia and myelodysplastic syndromes. The GVL benefit should always be compared to the possible toxic effects of GVHD. This article updates the initial SFGM-TC recommendations, proposed in 2013, that were focused on the use of DLI. Doses of DLI in the context of haplo-identical stem cell transplantation are now indicated. We confirm that remaining mobilized stem cells may be used as classical DLI. The definition and the place of preemptive and prophylactic DLI are precisely given. Recommendations regarding the quality of thawed DLI as well as necessary clinical and biological follow-up are also described in detail.Show less >
Show more >Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and low-grade lymphomas while the anti-tumoral activity is less in forms of acute leukemia and myelodysplastic syndromes. The GVL benefit should always be compared to the possible toxic effects of GVHD. This article updates the initial SFGM-TC recommendations, proposed in 2013, that were focused on the use of DLI. Doses of DLI in the context of haplo-identical stem cell transplantation are now indicated. We confirm that remaining mobilized stem cells may be used as classical DLI. The definition and the place of preemptive and prophylactic DLI are precisely given. Recommendations regarding the quality of thawed DLI as well as necessary clinical and biological follow-up are also described in detail.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2019-10-22T08:16:38Z